Humacyte’s (HUMA) Symvess has been awarded Electronic Catalog, or ECAT, listing approval from the U.S. Defense Logistics Agency. ECAT is an internet system that provides the Department of Defense, or DOD, and other federal agencies with access to manufacturers’ and distributors’ products. The approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at DOD and U.S. Department of Veterans Affairs facilities. Symvess was approved in the extremity vascular trauma indication by the FDA in December 2024. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte’s Symvess: A Promising Solution for Hemodialysis Challenges with Buy Rating
- Humacyte Approves Key Proposals at Annual Meeting
- Humacyte announces presentation of results from Phase 3 AV access study of V007
- Humacyte announces results in high-risk dialysis from V007 Pivotal Phase 3
- Largest borrow rate increases among liquid names